Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 156.16B, Pfizer(PFE) trades at $27.45. The stock has a price-to-earnings ratio of 20.39 and currently yields dividends of 6.2%.
During the trading session on 2026-02-12, Pfizer(PFE) shares reached a daily high of $27.89 and a low of $27.41. At a current price of $27.45, the stock is +0.1% higher than the low and still -1.6% under the high.
Trading volume for Pfizer(PFE) stock has reached 58.81M, versus its average volume of 59.56M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.94 and a low of $20.92.
PFE News
Daiwa analyst Narumi Nakagiri downgraded Pfizer (PFE) to Neutral from Outperform with a $27 price target Published first on TheFly – the ultimate source for re...
Pfizer (NYSE:PFE) received FDA Priority Review for a potential HYMPAVZI label expansion for pediatric and inhibitor-positive hemophilia patients. The company l...
Key Points Pfizer continues to lag the market due to poor financial results and upcoming challenges. However, the company is entering an important period in i...
Analyst ratings
57%
of 28 ratingsMore PFE News
Key Points Eli Lilly has a lofty 46 price-to-earnings ratio. Two other drugmakers have P/Es that are less than half of Eli Lilly's P/E. Eli Lilly's 0.6% yiel...
In early February 2026, Pfizer reported mixed 2025 financial results, reaffirmed 2026 revenue guidance, highlighted progress in its GLP-1 obesity pipeline, secu...
The stock has been fairly stable over the past year. Pfizer (PFE 0.70%) has been an underwhelming stock to own in recent years. Question marks about its growth...
Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjus...
If you are wondering whether Pfizer is genuinely good value or just looks cheap on the surface, this article walks through what the current numbers are really s...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer is running an early-stage clinical trial titled “An Interventional...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Advances Mid-Stage Trial of New Obesity Drug PF-07976016 Study Overview: This Pha...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.